Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback